Pfizer and biontech submit application to u.s. fda for emergency use authorization of omicron ba.4/ba.5-adapted bivalent vaccine booster in children 5 through 11 years of age

New york & mainz, germany--(business wire)--pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced they have completed a submission to the u.s. food and drug administration (fda) requesting emergency use authorization (eua) of a 10-Μg booster dose of the companies' omicron ba.4/ba.5-adapted bivalent covid-19 vaccine for children ages 5 through 11 years of age. the request for emergency use authorization of the omicron ba.4/ba.5-adapted bivalent vaccine in this age group is suppo
BNTX Ratings Summary
BNTX Quant Ranking